CD44v6、p53、PCNA在非小细胞肺癌中的表达研究

 目的　研究CD44v6、p53、PCNA三种基因蛋白与非小细胞肺癌 (NSCLC)临床病理特征的关系。方法　用S P免疫组化检测 74例NSCLC三种基因蛋白的表达。结果　CD44v6阳性表达与淋巴结有无转移、PTNM分期有显著差异 (P <0 .0 5)。p53阳性表达与肺癌细胞的分化程度、临床分期有显著差异 (P <0 .0 5)。PCNA染色强度指数与肺癌分化程度、淋巴结有无癌转移、PTNM分期有显著差异 (P <0 .0 5)。结论　CD44v6、p53、PCNA过表达与NSCLC的预后不良有密切关系 ,可作为临床评估、预测肿瘤转移潜能和预后的指标

A Study on Expression of CD44v6, p53, and PCNA Protein in Non-small Cell Lung Cancer

Objective To study the relationship between the expression of CD44v6, p53, PCNA protein and the clinical pathological characteristics of non small cell lung cancer (NSCLC). Methods Expression of CD44v6, p53, PCNA protein was detected in 74 NSCLC samples by immunohistochemistry. Results The positive rate of CD44v6 expression was significantly higher in NSCLC with lymph node metastasis 63.3% than that without lymph node metastasis 31.8% and PTNM stage ( P < 0.05 ). The positive rate of p53 in well cell differentiation group ( 28.6% ) was significantly higher than that in poor differentiation group ( 57.4% ) and PTNM stage ( P < 0.05 ).PCNA staining intensity index (SII) indicated close relationship between cell differentiation, lymph node metastasis and PTNM stage of NSCLC ( P < 0.05 ).Conclusion Overexpression of CD44v6, p53 and PCNA may be relative prognosis of the patient with NSCLC, and to predict metastasis and prognosis of NSCLC.